Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Single arm phase I/II study of ixazomib and romidepsin in relapsed/refractory PTCL. Each
cycle is 28 days. Patients will continue to receive therapy until progressive disease,
unacceptable toxicity, or if any other withdrawal criteria are met. The phase I study
includes three dose levels. The phase II study will include treatment with ixazomib and
romidepsin at the MTD established in the Phase I study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ryan Wilcox
Collaborators:
Takeda University of Michigan Cancer Center University of Michigan Rogel Cancer Center